A research team investigating children’s brain tumors has found promising results combining a hormone treatment with standard chemotherapy protocols. Triiodothyronine, commonly called T3, is a medication long used to manage thyroid disorders in patients throughout the lifespan. The hormone showed enhanced effectiveness when added to conventional cancer therapy in laboratory studies and animal models.
The fight against pediatric brain tumors has attracted plenty of research attention, and companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are leveraging the insights they get in their own research. This new approach could offer a low-cost, readily available adjunct to existing treatments, potentially reducing recurrence rates and improving outcomes for young patients.
The study, conducted by researchers at a major children’s hospital, tested T3 in combination with chemotherapy in cell lines and mouse models of medulloblastoma, the most common malignant brain tumor in children. Results showed that the combination significantly reduced tumor regrowth compared to chemotherapy alone. The hormone appears to sensitize cancer cells to the effects of chemotherapy, making them more vulnerable to treatment.
According to the lead author, the findings are particularly exciting because T3 is already FDA-approved and has a well-established safety profile. This could accelerate the path to clinical trials, bypassing some of the lengthy safety testing required for new compounds. The next step is to confirm these results in larger animal studies and eventually move to human trials.
Pediatric brain tumors are the leading cause of cancer-related death in children, and recurrence after initial treatment remains a major challenge. Current therapies, including surgery, radiation, and chemotherapy, can have debilitating long-term side effects. A therapy that could be added to existing regimens without significant additional toxicity would be a major advance.
The research team emphasizes that while these preclinical results are promising, they are still early. Further studies are needed to determine optimal dosing and timing of T3 administration. However, the potential for repurposing a well-known drug offers hope for faster translation to the clinic.
For more information on the research and related developments, visit TinyGems.
